Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting
HighReport
Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting
Carlsmed (NASDAQ:CARL) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $20.00 price target on the stock, up previously from $18.00.
LowReport
Carlsmed (NASDAQ:CARL) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $20.00 price target on the stock, up previously from $18.00.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: